BT8009 Phase II expansion first patient dosed; Phase I dose escalation complete

BICYCLE THERAPEUTICS PLC

Phase I dose escalation complete; RP2Ds: 5 mg/m2 weekly and 7.5 mg/m2 (2 on, 1 off) selected.
Confirmed RECIST responses in UC and NSCLC; median duration of response not yet reached.
First patient dosed in Phase II expansion; includes cohorts evaluating BT8009 with CPI.
Priority indication: first-line metastatic UC in cisplatin-ineligible patients combined with CPI.
Updated Phase I data from 49 patients to be presented at medical meeting in 1H 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.